Sanguine Biosciences

Executive Summary

Sanguine Biosciences is a pioneering US-based company that specializes in at-home biospecimen collection and research services, accelerating drug discovery and development by connecting patients directly with researchers. Founded in 2010 and operating at the intersection of diagnostics and genomics, the company reduces patient burden by offering convenient, at-home sample collection kits for high-quality, consented biological samples and associated clinical data. This streamlined approach enables faster, more efficient clinical trials and translational research, addressing a critical bottleneck in the pharmaceutical R&D process. By improving sample accessibility and patient recruitment, Sanguine supports a wide range of therapeutic areas and positions itself as a key enabler of decentralized clinical trials. Leveraging its established infrastructure and focus on patient-centricity, Sanguine is well-positioned to capture growing demand for real-world evidence and home-based research solutions. The company's ability to deliver reliable, ethically sourced biospecimens from diverse populations strengthens its value proposition to biopharma partners. With the rise of personalized medicine and the need for richer biomarker data, Sanguine's services are increasingly integral to early-stage drug development and post-market surveillance. Looking ahead, the company may pursue strategic partnerships, expand its test menu, or broaden its geographic footprint to deepen its impact on the clinical research landscape.

Upcoming Catalysts (preview)

• Q4 2026Expansion into oncology and rare disease sample collection programs60% success
• Q1 2027Announcement of a major partnership with a top-20 pharmaceutical company for decentralized trial sample logistics50% success
• Q3 2026Launch of a digital platform integrating real-time sample tracking and patient engagement features70% success